Sutro Biopharma, Inc. (STRO) Misses Q1 EPS by 6c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q1 EPS of ($0.91), $0.06 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $17.39 million versus the consensus estimate of $9 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight